Rapid Infectious Disease Testing Picks Up Speed

Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.

Antimicrobial testing

Several recent events highlight an increase in the pace of innovation in rapid infectious disease testing. In July, Accelerate Diagnostics Inc. filed a De Novo request to the US Food and Drug Administration for Evaluation of Automatic Class III Designation of its system for pathogen identification and antibiotic susceptibility testing (AST). A week and a half earlier, Cepheid obtained clearance from FDA for expanded claims to its Xpert Carba-R test for detecting carbapenem resistance genes in multidrug-resistant organisms using rectal swabs in addition to bacterial isolates, significantly cutting testing time. Two months earlier, Luminex Corp. completed a tender offer for bloodstream infectious disease test specialist Nanosphere Inc. for $77 million. [See Deal] Also in May, the Merck Global Health Innovation Fund (Merck GHI) increased its investment in OpGen Inc. to help fund OpGen’s bioinformatics-heavy platform for infection detection and control. [See Deal] These moves after Roche drew attention to the space last summer when it paid $190 million up front and promised another $235 million in product-related milestones for GeneWEAVE Biosciences Inc. and its platform for rapidly detecting multidrug-resistant organisms and analyzing AST or resistance. [See Deal]

“There has been a lot of investment in product development in microbiology, defined broadly to include molecular products that sit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

This Belgian Biotech’s Drug Cocktail Could Help Reverse Muscle Aging

 
• By 

While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By 

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By 

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.